Pacific Therapeutics (PCFTF) 0.0080 $PCFTF Global

New Post Public Reply Private Reply Replies (0) Message Board

Oct 10, 2015 at 11:49 AM

Pacific Therapeutics (PCFTF) 0.0080 $PCFTF

Global Erectile Dysfunction Pipeline Review 2015
M2 - Tue Sep 08, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhsbsn/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Apricus Biosciences, Inc. - Aprogen, Inc. - Bioheart, Inc. - Biolab Sanus Farmaceutica Ltda. - Corridor Pharmaceuticals Inc. - Futura Medical Plc - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Mezzion Pharma Co. Ltd. - Mitsubishi Tanabe Pharma Corporation - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Pacific Therapeutics Ltd. - Palatin Technologies, Inc. - Pharmicell Co., Ltd. - Sagene Pharmaceuticals, Inc. - Suda Ltd - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bhsbsn/erectile
PTN: 0.80 (unch), APRI: 1.65 (+0.03), ACOR: 29.89 (-0.22)

Liver Cirrhosis Pipeline Review, H1 2015 - 12 Key Comapnies
M2 - Thu Jun 11, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2ctvbp/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - Gilead Sciences, Inc. - GNI Group Ltd. - Pacific Therapeutics Ltd. - PharmaIN Corporation - Pharmicell Co., Ltd. - S-Evans Biosciences, Inc. - Stelic Institute & Co. - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/2c..._cirrhosis
GILD: 100.65 (-0.16), CNAT: 4.21 (-0.06), GALT: 2.61 (-0.10)

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cp3333/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - AnaptysBio, Inc. - Auspex Pharmaceuticals, Inc. - Biogen Idec Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - HanAll Biopharma Co., Ltd. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Kadmon Corporation, LLC - Kasiak Research Pvt. Ltd. - Kyorin Pharmaceutical Co., Ltd. - Lanthio Pharma B.V. - LTT Bio-Pharma Co., Ltd. - MedImmune, LLC - Moerae Matrix, Inc. - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. For more information visit http://www.researchandmarkets.com/research/cp3333/idiopathic
BIIB: 269.16 (-10.72), ASPX: 100.96 (unch), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), GILD: 100.65 (-0.16), CGEN: 5.68 (-0.02), IBIO: 0.68 (unch), FGEN: 21.77 (+0.22), CELGZ: 1.74 (+0.04), FPRX: 15.48 (-0.04)

Pacific Therapeutics Ltd. Announces United States Issuance of Patent for Treating Fibrosis
TheNewswire.ca - Mon Jun 01, 7:37AM CDT
(via Thenewswire.ca)
PT: 0.66 (-0.03)

IIROC Trade Resumption - PT
CNW Group - Tue May 19, 1:50PM CDT
Trading resumes in:

Pacific Therapeutics Signs LOI to Sell Fibrosis and Erectile Dysfunction Therapeutics Technologies
ACCESSWIRE - Tue May 19, 1:31PM CDT
VANCOUVER, BC / ACCESSWIRE / May 19, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.

IIROC Trading Halt - PT
CNW Group - Tue May 19, 1:22PM CDT
The following issues have been halted by IIROC:

Pacific Therapeutics Announces Extension of Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Tue Apr 28, 3:20PM CDT
VANCOUVER, BC / ACCESSWIRE / April 28, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.

Pacific Therapeutics Ltd. Announces Change Of Auditor
ACCESSWIRE - Wed Apr 22, 7:17PM CDT
VANCOUVER, BC / ACCESSWIRE / April 22, 2015 / Pacific Therapeutics Ltd. (CNSX: PT) (Frankfurt: 1P3) (the "Company"

announces that, effective April 22, 2015 it has changed auditors. on April 16, 2015 the Company announced the resignation of James Stafford Inc. Chartered Accountants as its auditor.
PT: 0.66 (-0.03)

Pacific Therapeutics Ltd. Announces United States Allowance of Patent for Treating Fibrosis
ACCESSWIRE - Fri Apr 10, 7:41AM CDT
VANCOUVER, BC / ACCESSWIRE / April 10, 2015 / Pacific Therapeutics Ltd. (CNSX: PT) (OTC

CFTF) (1P3.F) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing approved drugs for large markets.
PT: 0.66 (-0.03)

Pacific Therapeutics Announces Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Wed Apr 01, 6:15PM CDT
VANCOUVER, BC / ACCESSWIRE / April 1, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (PINKSHEETS: PCFTF) (Frankfurt: 1P3) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.

Pacific Therapeutics Announces Closing of Non-Brokered Financing
ACCESSWIRE - Mon Mar 23, 7:40AM CDT
VANCOUVER, BC / ACCESSWIRE / March 23, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.

Pacific Therapeutics Announces Non-Brokered Financing
ACCESSWIRE - Mon Feb 16, 1:12PM CST
VANCOUVER, BC / ACCESSWIRE / February 16, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cboe Global Hits Record Index Options Volume in October

October's Market Landscape: Peaks and Troughs Sometimes you look at market reports and it feels like you're staring at a rollercoaster's wild ride. This past October was a month full of twists for Cboe Global Markets, Inc. (Cboe: CBOE). With trading volumes shifting dramatically across its various segments, Cboe delivered some impressive highlights against a mixed...

MY DR NOW Expands: Seven-Day Clinics Open Everywhere

Breaking The Mold Of Traditional Medicine MY DR NOW isn't here to play by the age-old rules. They're slinging open the doors to their newest family medicine clinics and kicking the old Monday-to-Friday scheduling straight to the curb. Every single day of the week, from 8 a.m. to 8 p.m., patients in Sunnyvale and Tucson are getting a dose of healthcare that's all about...

Zillow Eases the FHA Down Payment Burden

A New Financial Lifeline for Homebuyers In a market where finding a foothold in the housing game feels like scaling Everest without ropes, Zillow Home Loans has tossed a lifeline to potential homeowners. Their latest move might just be what many house hunters needed to hear—offering a hand where it’s been missing for years: down payment assistance for FHA loans. The...

Elite Academy Takes Bold Step in Ethical AI for Schools

Pioneering New Fronts in Education with AI Elite Academic Academy, a stalwart in California's public charter school landscape, has just taken a significant stride forward by stepping into the EDSAFE AI Alliance District Policy Lab. The move, announced in early November 2026, sees Elite diving into the intricate world of artificial intelligence in education, with a pointed...

WellNet Embraces Voice AI for Provider Calls

Ever met a TPA grappling over their provider call costs like a crusty sailor with a rusted anchor? Welcome to WellNet Healthcare, folks. They've tapped EHVAhealth's conversational voice AI to take a solid swing at automating those burdensome provider calls. They're no stranger to the chaos of managing member eligibility and benefits verification, and this move might just...

Hidden Costs of Lineworker and CDL Training in California

The True Financial Picture of Skilled Trade Programs Ever wonder why that flashy tuition number doesn't line up with your wallet by the end of your training days? That's the reality smashing aspiring lineworkers and future truck drivers in Northern California right in the face. We're talking about a full breakdown here, beyond what the glossy brochures ever tell you....

Fedora and Clarion Boost Oncology Practice Performance

Hell of a Pair-Up: Fedora and Clarion Focus on Oncology Well, here's a setup that doesn't scream about blue chip stocks—but it's swimming in opportunity all the same. Fedora Healthcare Solutions just shook hands with Clarion, cementing a deal that's piqued my interest for its potential to green-light some real progress for independent oncology practices. These are not...

Exiger Lands $12M Deal with USAF for ICBM Insights

Exiger's New Partnership: A $12M Heavyweight Move The Air Force isn’t about to let its guard down when it comes to those intercontinental ballistic missiles. Nope, the powers that be have decided it’s time to pump some serious dough into the chain that keeps those missiles ready to go, handing $12 million over to Exiger to light the path through the complex web of the...

Class Action Targets Extremist Groups, Interference

Legal Spar on the Horizon: Class Action Commences The legal world now sees a fresh duel as Impresa Legal Group rolls up its sleeves and files a class action lawsuit against certain extremist groups and foreign-funded entities. At the heart of this legal action are accusations that these outfits have orchestrated a campaign to intimidate data center workers while meddling...

Centrus Energy's Quarter Ups and Downs Unpacked

Stirring the Pot: Centrus Energy's Rollercoaster Quarter Trading never fails to serve up surprises, and Centrus Energy Corp. (NYSE:LEU) is dishing them out this quarter. Despite a revenue slip to $55.5 million from last year’s $74.9 million, GAAP net income rocketed to a whopping $31.6 million. Talk about a mixed bag of fortunes. Diving Deeper into the Numbers Revenue...